Papers

2017

Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2017;23(7):1785-1796.

2015

Armstrong AE, Weese-Mayer DE, Mian A, Maris JM, Batra V, Gosiengfiao Y, et al. Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. Pediatric blood & cancer. 2015 May 22. PubMed PMID: 26011159.

2013

Batra V, Sands SA, Holmes E, Geyer JR, Yates A, Becker L, et al. Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: A report from the Children's Oncology Group. Pediatric blood & cancer. 2013 Aug 23. PubMed PMID: 24038913.

Abstracts

2017

Batra V et al Meta-[211At]astatobenzylguanidine ([211At]MABG) is a potent alpha particle emitting systemic targeted radiotherapeutic in preclinical models of neuroblastoma. AACR Annual Meeting, Washington, D.C.; April 2017.

Welsh S, Rosenblatt S, Batra V, Betensky M, Ichord R, Himebauch A progressive malignant arterial ischemic stroke: A rare presentation of pediatric APL. Society for Critical Care Medicine conference. Hawaii; January 2017.

2016

Batra V et al Preclinical characterization of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma. Oral presentation at ANR Cairns, Australia June 2016.

Huibregtse K, Vo K, Dubois S, Fetzko S, Batra V et al Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131Imetaiodobenzylguanidine Oral presentation (Huibregtse K) at ANR Cairns, Australia;  June 2016

DuBois S, Mody R, Van Ryn C, Naranjo A, Kreissman S, Baker DL, Parisi M, Barry Shulkin B, Maris JM, Batra V et al Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG) Oral presentation (DuBois S) at ANR Cairns, Australia; June 2016. 

Batra V et al Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations J Nucl Med 2016 57:1787. 

Shulkin B, Maris JM, Batra V et al Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG). Meeting abstracts J Clin Oncol 34, 2016 (suppl; abstr 10526) ASCO Annual Meeting May 2016.

2015

Batra V et al Development of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma AACR Annual Meeting, Philadelphia PA April 2015

Hart L, Chen L, Batra V et al Combined MEK1/2 and PI3K Inhibition Induces Synergistic Caspase-Dependent Apoptosis in Neuroblastoma, AACR Annual Meeting, Philadelphia PA April 2015

2014

Chacko AM, Batra V et al Ultratrace meta-211At-astatobenzylguanidine (211At-MABG) for targeted radiotherapy of neuroendocrine cancer Journal of Nuclear Medicine Meeting abstracts May 2014; 55: 1075.

Bhatia A, Batra V et al Soft Tissue Neuroblastoma Response to 131I-MIBG therapy in the Pediatric Population. Meeting abstracts Pediatric Radiology June 2014, Volume 44, Issue 2 Supplement, pp 255-402

Books

Chapters

Batra V, Deyell R, Maris JM chapter: Molecular oncology of neuroblastoma in Molecular Oncology: Causes of Cancer and Targets for Treatment Charles Sawyers, Frank Rauscher and Edward Gelmann (eds.). Cambridge University Press.

Posters and Presentations

2014

Hart L, Rader J, Raman P, Batra V et al Combined inhibition of CDK4/6 and MEK1/2 in preclinical models of neuroblastoma. Poster, ANR, Cologne, Germany, May 2014.

Batra V et al Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma. Poster, AACR Pediatric Oncology Conference November 2013, Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes and Poster Presentation at CHOP Poster day February 2014.

2013

Hart L, Batra V et al MEK 1/2 inhibition and biomarkers of response in preclinical models of neuroblastoma. Poster, AACR Pediatric Oncology Conference November 2013, Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes.

Invited Lectures

2014

Rob Forrest Memorial Symposium on Medical Health Physics ‘Targeted Radiotherapy for the childhood cancer Neuroblastoma’ Thomas Jefferson University. December 2014